FATE
Fate TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Fate has a defined near-term clinical milestone in RECLAIM-LN, FDA CDRP and RMAT support for FT819, and management reported an operating runway into 2028 after reducing first-quarter operating expenses by 20% year over year [#SEC-8K-2026-05-13].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +2.4.
What can break
Additional equity compensation or financing could dilute shareholders [#8-K-2026-06-15].
Momentum
95
Value
41
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.30 · Bull $5.40 · Bear $1.75
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.41
Why
Momentum95 · Δ7d +2.4
Value41 · Δ7d -0.1
Sentiment63 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
95
26% active weight
Current posture
7d trendSoftening
Δ7d
+2.4
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
63
34% active weight
Current posture
7d trendImproving
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 94.6 / Value 41.1 / Sentiment 62.7
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$324.04M
Beta
2.25
Shares Out
116.56M
P/E (TTM) · Derived
-2.4
P/S (TTM)
16.32
P/FCF (TTM) · Derived
-3.07
Rev YoY
-20.3%
EPS YoY
-18.2%
Gross Margin
-97.7%
Op Margin
-2448.2%
Net Debt
-$125.81M
Current Ratio
5.85
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology